Lipid peroxidation products and antioxidants in human disease

Environmental Health Perspectives

Volumn 106, Issue SUPPL. 5, 1998, Pages 1229-1234

  Romero, Francisco J ^a   Bosch Morell, Francisco ^a   Romero, María J ^a   Jareño, Enrique J ^a   Romero, Belén ^a   Marín, Nuria ^a   Romá, Joaquin ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

4 Hydroxynonenal; Alzheimer's disease; Antioxidants; Glutathione; Glutathione peroxidase; Hepatitis C; Human immunodeficiency virus; Interferon 2; Lipid peroxidation; Malondialdehyde; Oxidative stress; Retinal detachment; amyloid

Indexed keywords

4 HYDROXYNONENAL; ANTIOXIDANT; GLUTATHIONE PEROXIDASE; MALONALDEHYDE;

CONFERENCE PAPER; DIABETES MELLITUS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID PEROXIDATION; MOUSE; MYOPIA; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL NERVE; PRIORITY JOURNAL; RAT; RETINA DETACHMENT; SUBRETINAL FLUID;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0031762824     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.98106s51229     Document Type: Conference Paper

References (89)

1. Sies H. Oxidative Stress: Introductory Remarks. In: Oxidative Stress (Sies H, ed). London:Academic Press, 1985;1-8.
2. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radie Biol Med 11:81-128 (1991).
3. Romero MJ, Bosch-Morell F, Romero B, Rodrigo JM, Serra MA, Romero FJ. Serum malondialdehyde: possible use for the clinical management of chronic hepatitis C patients. Free Radic Biol Med (in press).
4. Jareño EJ, Bosch-Morell F, Fernández-Delgado R, Donat J, Romero FJ. Serum malondialdehyde in HIV seropositive children. Free Radic Biol Med 24:503-506 (1998).
5. Bosch-Morell F, Sanz A, Díaz-Llopis M, Romero FJ, Lipid peroxidation products in human subretinal fluid. Free Radic Biol Med 20:899-903 (1996).
6. Hermenegildo C, Raya A, Romá J, Romero FJ. Decreased glutathione peroxidase activity in sciatic nerve of alloxan-induced diabetic mice and its correlation with blood glucose levels. Neurochem Res 18:893-896 (1993).
7. Bosch-Morell F, Martínez-Soriano F, Colell A, Fernández-Checa JC, Romero FJ. Chronic ethanol feeding induces cellular antioxidants decrease and oxidative stress in rat peripheral nerves. Effect of S-adenosyl-L-methionine and N-acetyl-L-cysteine. Free Radie Biol Med 25:365-368 (1998).
8. Uchida K, Stadtman ER. Modification of histidine residues in proteins by reaction with 4-hydroxynonenal. Proc Natl Acad Sci USA 89:4544-4548 (1992).
9. Szweda LI, Uchida K, Tsai L, Stadtman ER. Inactivation of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonenal. Selective modification of an active-site lysine. J Biol Chem 268:3342-3347 (1993).
10. Hartley DP, Lindahl R, Petersen DR. Covalent modification of class 2 and class 3 aldehyde dehydrogenase by 4-hydroxynonenal. Adv Exp Med Biol 372:93-101 (1995).
11. +-ATPase. Free Radic Biol Med 20:215-223 (1996).
12. Müller WEG, Romero FJ, Pergande G, Perovic S. Flupirtine: a neuroprotective agent against β-amyloid-induced apoptosis in vitro. J Brain Res 37:575-577 (1996).
13. Müller WEG, Romero FJ, Perovic S, Pergande G, Pialoglou P. Protection of flupirtine on β-amyloid-induced apoptosis in neuronal cells in vitro. Prevention of amyloid-induced glutathione depletion. J Neurochem 68:2371-2377 (1997).
14. Romero FJ, Zukowski D, Mueller-Klieser W. Glutathione content of V79 cells in two- and three-dimensional culture. Am J Physiol 272:C1507-C1512 (1997).
15. Martíez MC, Bosch-Morell F, Raya A, Romá J, Aldasoro M, Vila J, Lluch S, Romero FJ. 4-Hydroxynonenal, a lipid peroxidation product, induces relaxation of human cerebral arteries. J Cerebr Blood Flow Metab 14:693-696 (1994).
16. Romero FJ, Romero MJ, Bosch-Morell F, Martínez MC, Medina P, Lluch S. 4-Hydroxynonenal-induced relaxation of human mesenteric arteries. Free Radic Biol Med 23:521-523 (1997).
17. Suematsu T, Kamada T, Abe H, Kikuchi S, Yagi K. Serum lipid peroxide level in patients suffering from liver diseases. Clin Chim Acta 79:267-270 (1977).
18. Suematsu T, Matsumura T, Sato N. Lipid peroxidation in alcoholic liver disease in humans. Alcohol Clin Exp Res 5:427-430 (1981).
19. Yagi K. Lipid peroxides and human diseases. Chem Phys Lipids 45:337-351 (1987).
20. Higueras V, Raya A, Rodrigo JM, Serra MA, Romá J, Romero FJ. Interferon decreases serum lipid peroxidation products of hepatitis C patients. Free Radic Biol Med 15:131-133 (1994).
21. Alter HJ, Purcell RH, Holland PV, Feinstone SM, Morrow AG, Moritsugu Y. Clinical and serological analysis of transfusion-associated hepatitis. Lancet ii:838-841 (1975).
22. Dienstag JL, Isselbacher KJ. Chronic hepatitis. In: Harrison's Principles of Internal Medicine (Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds). New York: McGraw-Hill, 1994;1478-1483.
23. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 25:449-458 (1997).
24. Stuyver L, Fretz C, Esquivel C, Boudifa A, Jaulmes D, Azar N, Lunel F, Leroux-Roels G, Maertens G, Fournel JJ. Hepatitis C virus (HCV) genotype analysis in apparently healthy anti-HCV-positive parisian blood donors. Transfusion 36:552-558 (1996).
25. Garcia-Fulgueiras A, Tormo MJ, Rodriguez T, Perez-Flores D, Chirlaque D, Navarro C. Prevalence of hepatitis B and C markers in the southeast of Spain: an unlinked community-based serosurvey of 2203 adults. Scand J Infect Dis 28:17-20 (1996).
26. Soetjipto, Handajani R, Lusida MI, Darmadi S, Adi P, Soemarto, Ishido S, Katayama Y, Hotta H. Differential prevalence of hepatitis C virus subtypes in healthy blood donors, patients on maintenance hemoaialysis, and patients with hepatocellular carcinoma in Surabaya, Indonesia. J Clin Microbiol 34:2875-2880 (1996).
27. Alter HJ. Clinical, virological and epidemiological basis for the treatment of chronic non-A, non-B hepatitis. J Hepatol 11:519-525 (1990).
28. Seymour C. Asymptomatic infection with hepatitis C virus. Br Med J 308:670-671 (1994).
29. Berger A, vonDepka-Prondzinski M, Doerr HW, Rabenau H, Weber B. Hepatitis C plasma viral load is associated with HCV genotype but not with HIV coinfection. J Med Virol 48:339-343 (1996).
30. Iuliano R, Pizzigallo AM, Alecci A, Barsanti L, Trovato R, Forastieri G, Lico S, Palmieri C, Brizzi M, Marino N, et al. Quantitation of HCV viremia by branched DNA signal amplification in patients treated with α-interferon-a longitudinal study. Infection 24:292-296 (1996).
31. Quiroga JA, Bosch O, Gonzalez R, Marriott E, Castillo I, Bartolome J, Carreno V. Immunoglobulin M antibody to hepatitis C virus during interferon therapy for chronic hepatitis C. Gastroenterology 103:1285-1289 (1992).
32. Quiroga JA, Martin J, Pardo M, Carrefio V. Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to interpheron alpha. Dig Dis Sci 39:2485-2496 (1994).
33. Kondo M, Tanaka K, Ikeda M, Arata S, Saito S, Sakaguchi T, Morimoto M, Fujii T, Mitsui K, Okazaki H, et al. Hepatic HCV-RNA as a predictor of outcome after interferon treatment in patients with chronic hepatitis C. J Gastroenterol Hepatol 11:236-240 (1996).
34. Stanley AJ, Haydon GH, Piris J, Jarvis LM, Hayes PC. Assessment of liver histology in patients with hepatitis C and normal transaminase levels. Eur J Gastroenterol Hepatol 8:869-872 (1996).
35. Barbaro G, Di-Lorenzo G, Soldini M, Parrotto S, Bellomo G, Belloni G, Grisorio B, Barbarini G. Hepatic glutathione deficiency in chronic hepatitis C: quantitative evaluation in patients who are HIV positive and HIV negative and correlations with plasmatic and lymphocytic concentrations and with the activity of the liver disease. Am J Gastroenterol 91:2569-2573 (1996).
36. Inchauspe G. Protection and defence mechanisms in HCV infection. Nephrol Dial Transplant 11(Suppl 4):6-8 (1996).
37. Buhl R, Holroyd KJ, Mastrangeli A, Cantin AM, Jaffe HA, Wells FB, Saltini C, Crystal RG. Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet iii:1294-1298 (1989).
38. Staal FJT, Roederer M, Israelski DM, Bubp J, Mole LA, McShane D, Deresinski SC, Ross W, Jussman H, Raju PA. Intracellular glutathione levels in T cell subsets decrease in HIV infected individuals. AIDS Res Hum Retroviruses 8:305-311 (1992).
39. Sönnerborg A, Carlin G, Akerlund B, Jarstrand C. Increased production of malondialdehyde in patients with HIV infection. Scand J Infect Dis 20:287-290 (1988).
40. Eck HP, Stahl-Henning C, Hunsmann G, Dröge W. Metabolic disorder as early consequence of simian immunodeficiency virus infection in rhesus macaques. Lancet 338:346-347 (1991).
41. Navel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326:711-713 (1987).
42. Roederer M, Staal FJT, Raju PA, Ela SW, Herzenberg LA, Herzenberg LA. Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine. Proc Natl Acad Sci USA 87:4884-4888 (1990).
43. Suzuki YJ, Aggarwal BB, Packer L. α-Lipoic acid is a potent inhibitor of NF-κB activation in human T cells. Biochem Biophys Res Commun 189:1709-1715 (1992).
44. Arpadi S, Caspe WB. HIV Testing. J Pediatr 119:S8-S13 (1991).
45. Romero FJ, Jareno EJ, Fernandez- Delgado R, Donat J, Bosch-Morell F. Unpublished data.
46. Jareno EJ, Bosch-Morell F, Fernández-Delgado R, Donat J, Romero FJ. Serum malondialdehyde in HIV seropositive chidren negatively correlates with CD4+ lymphocytes count. Biofactors 8:129-132 (1998).
47. Fahey JL, Taylor JMG, Detels R, Hofmann B, Melmed R, Nishanian P, Giorgi JV. The pronostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 322:166-172 (1990).
48. Cavert W, Notermans DW, Staskus K, Wietgrefe SW, Zupancic M, Gebhard K, Henry K, Zhang Z, Mills R, McDade H et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276:960-964 (1997).
49. Michels RG, Wilkinson CP, Rice TA. Retinal Detachment. St. Louis, MO:C.V. Mosby, 1990.
50. Bazan NG. The metabolism of omega-3 polyunsaturated fatty acids in the eye: the possible role of docosanexanoic acid and docosanoids in retinal physiology and ocular pathology. Prog Clin Biol Res 312:95-112 (1989).
51. Bazan NG. Lipid Mediators in Eye Inflammation. Basel:Karger, 1990.
52. Hackett SF, Conway BP, Campochiaro PA. Subretinal fluid stimulation of retinal pigment epithelial cell migration is dependent on certain features of the detachment or its treatment. Arch Ophthalmol 107:391-394 (1989).
53. Goto H, Wu GS, Gritz DC, Atalla LR, Rao NA. Chemotactic activity of the peroxidized retinal membrane lipids in experimental autoimmune uveitis. Curr Eye Res 10:1009-1014 (1991).
54. Puertas FJ, Cano-Parra J, Muñoz G, Bosch-Morell F, Romá J, Díaz-Llopis M, Cortés V, Romero FJ. 4-Hydroxynonenal-induced inflammation in the rabbit eye [Abstract]. Invest Ophthalmol Vis Sci 35:1885 (1994).
55. Bosch-Morell F, Díaz-Llopis M, Raya A, Hermenegildo C, Puertas FJ, Romá J, Romero FJ. Novel aspects of antioxidants and lipid peroxidation in ophthalmic disease. Life Chem Reports 12:101-104 (1994).
56. Dorey CK, Khouri GG, Syniuta LA, Curran SA, Weiter JJ. Superoxide production by porcine retinal pigment epithelium in vitro. Invest Ophthalmol Vis Sci 30:1047-1054 (1989).
57. Puertas FJ, Díaz-Llopis M, Chipont E, Romá J, Raya A, Romero FJ. Glutathione system of human retina. Enzymatic conjugation of lipid peroxidation products. Free Radic Biol Med 14:549-551 (1993).
58. McNeil JD, Wiebkin OW, Betts WH, Cleland LG. Depolymerisation products of hyaluronic acid after exposure to oxygen-derived free radicals. Ann Rheum Dis 44:780-789 (1985).
59. Greenwald RA, Moak SA. Degradation of hyaluronic acid by polymorphonuclear leukocytes. Inflammation 10:15-30 (1986).
60. Romero FJ. Antioxidants in peripheral nerve. Free Radic Biol Med 20:925-932 (1996).
61. Kihara M, Schmelzer JD, Poduslo JF, Curran GL, Nickander KK, Low PA. Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci USA 88:6107-6111 (1991).
62. Martínez-Blasco A, Hermenegildo C, Bosch-Morell F, Romero FJ. Role of oxidative stress in experimentally-induced diabetic neuropathy: mechanisms involved [Abstract]. J Physiol 493.P:104S (1996).
63. Martínez-Blasco A, Bosch-Morell F, Trenor C, Romero FJ. Experimental diabetic neuropathy: role of oxidative stress and mechanisms involved. Biofactors 8:41-43 (1998).
64. Low PA, Nickander KA. Oxygen free radical effects in sciatic nerve in experimental diabetes. Diabetes 40:873-877 (1991).
65. Nagamatsu M, Nickander K, Schmelzer JD, Raya A, Wittrock DA, Tritschler H, Low PA. Lipoic acid improves nerve blood flow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 18:1160-1167 (1995).
66. Jensson H, Guthenberg C, Ålin P, Mannervik B. Rat glutathione transferase 8-8 an enzyme efficiently detoxifying 4-hydroxy-alk-2-enals. FEBS Lett 203:207-209 (1986).
67. Danielson UH, Esterbauer H, Mannervik B. Structure-activity relationship of 4-hydroxy-alkenals in the conjugation catalyzed by mammalian glutathione transferases. Biochem J 247:707-713 (1987).
68. Bosch-Morell F, Flohé L, Marín N, Romero FJ. 4-Hydroxynonenal inhibits glutathione peroxidase: protection by glutathione. Free Radic Biol Med (in press).
69. Schauer RJ, Zollner H, Esterbauer H. Biological effects of aldehydes with particular attention to 4-hydroxynonenal and malondialdehyde. In: Membrane Lipid Oxidation (Vigo-Pelfrey C, ed). Boca Raton, FL:CRC Press, 1991;141-163.
70. Braughler JM, Hall ED. Central nervous system trauma and stroke. I. Biochemical considerations for oxygen radical formation and lipid peroxidation. Free Radic Biol Med 6:289-301 (1989).
71. Hall ED, Braughler JM. Central nervous system trauma and stroke. II: Physiological and pharmacological evidence for involvement of oxygen radicals and lipid peroxidation. Free Radic Biol Med 6:303-313 (1989).
72. Lebel CP, Bondy SC. Oxygen radicals. Common mediators of neurotoxicity. Neurotoxicol Teratol 13:341-346 (1991).
73. Pigeolet E, Corbisier P, Houbion A, Lambert D, Michiels C, Raes M, Zachary M-D, Remacle J. Glutathione peroxidase, Superoxide dismutase and catalase inactivation by peroxides and oxygen derived free radicals. Mech Ageing Dev 51:283-297 (1990).
74. Meister A. Glutathione metabolism and its selective modification. J Biol Chem 263:17205-17208 (1988).
75. Romero FJ, Monsalve E, Hermenegildo C, Puertas FJ, Higueras V, Nies E, Segura-Aguilar J, Romá J. Oxygen toxicity in the nervous tissue: comparison of the antioxidant defense of rat brain and sciatic nerve. Neurochem Res 16:157-161 (1991).
76. Mark RJ, Lovell MA, Markesbery WR, Uchida K, Mattson MP. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J Neurochem 68:255-264 (1997).
77. Ceballos I, Javoy-Agid F, Delacourte A, Defossez A, Nicole A, Sinet PM. Parkinson's disease and Alzheimer's disease: neurodegenerative disorders due to brain antioxidant system deficiency? Adv Exp Med Biol 264:493-498 (1990).
78. Goetz ME, Freyberger A, Hauer E, Burger E, Sofic E, Gsell W, Heckers S, Jellinger K, Hebenstreit G, Froehlich L, et al. Susceptibility of brains from patients with Alzheimer's disease to oxygen-stimulated lipid peroxidation and differential scanning calorimetry. Dementia 3:213-222 (1992).
79. Sies H. Ebselen, a selenoorganic compound as glutathione peroxidase mimic. Free Radic Biol Methods 14:313-323 (1993).
80. Sies H. Ebselen. Meth Enzymol 252:341-342 (1995).
81. Hubel CA, Davidge ST, McLaughlin MK. Lipid hydroperoxides potentiate mesenteric artery vasoconstrictor responses. Free Radic Biol Med 14:397-407 (1993).
82. van der Kraaij AMM, de Jonge HR, Esterbauer H, de Vente J, Steinbusch HWM, Foster JF. Cumene hydroperoxide, an agent inducing lipid peroxidation, and 4-hydroxy-2,3-nonenal, a peroxidation product, cause coronary vasodilatation in perfused rat hearts by a cyclic nucleotide independent mechanism. Cardiovasc Res 24:144-150 (1990).
83. Kaneko T, Kaji K, Matsuo M. Cytotoxicities of a linoleic acid hydroperoxide and its related aliphatic aldehydes toward cultured human umbilical vein endothelial cells. Chem Biol Interact 67:295-304 (1988).
84. Selley ML, Bartlett MR, McGuiness JA, Hapel AJ, Ardlie NG, Lacey MJ. Determination of the lipid peroxidation product trans-4-hydroxy-2-nonenal in biological samples by high performance liquid chromatography and combined capillary gas chromatography/negative ion chemical ionization mass spectrometry.J Chromatogr 488:329-340 (1989).
85. Esterbauer H, Zollner H, Schaur RJ. Aldehydes formed by lipid peroxidation, mechanisms of formation, occurrence and determination. In: Membrane Lipid Oxidation, Vol I (Vigo-Pelfrey C, ed). Boca Raton, FL:CRC Press, 1990;239-283.
86. Kamimura S, Gaal K, Britton RS, Bacon BR, Triadafilopoulos G, Tsukamoto H. Increased 4-hidroxynonenal levels in experimental alcoholic liver disease: association of lipid peroxidation with liver fibrogenesis. Hepatology 16:448-453 (1992).
87. Esterbauer H, Cheeseman KH. Determination of aldehydic lipid peroxidation products: malondialdehyde and 4-hydroxynonenal. Methods Enzymol 186:407-421 (1990).
88. Tsukamoto H. Oxidative stress, antioxidants, and alcoholic liver fibrogenesis. Alcohol 10:465-467 (1993).
89. Fuchs J, Schofer H, Milbradt R, Freisleben HJ, Buhl R, Siems W, Grune T. Studies on lipoate effects on blood redox state in human immunodeficiency virus infected patients. Arzneimforsch 43:1359-1362 (1993).